Assessment of the tolerability and efficacy of ProstOptima in combination therapy in patients with benign prostatic hyperplasia and mild-to-moderate lower urinary tract symptoms

Cover Page

Cite item

Full Text

Abstract

Background. Benign prostatic hyperplasia (BPH) is one of the most common disorders in middle-aged and older men. In the past 10 years, there has been an upward trend in BPH incidence in younger subjects, emphasizing the need for more careful diagnosis by urologists and adequate pharmacotherapy to alleviate the lower urinary tract symptoms (LUTS) and prevent the need for surgical intervention. Recently, combination therapy (α1-blocker and phytotherapeutic agent) has been increasingly used in the management of LUTS due to its positive clinical outcomes and ability to enhance patient quality of life.

Aim. To evaluate the clinical efficacy of the combination of ProstOptima and α1-blocker (tamsulosin) in the treatment of BPH-related mild to moderate LUTS.

Materials and methods. The study included 76 males with BPH and mild-to-moderate LUTS. The patients were randomized into two groups of 38 subjects each. Group 1 (n=38) received standard therapy with tamsulosin 0.4 mg QD for 2 months, Group 2 (n=38) received combination therapy with tamsulosin 0.4 mg QD and ProstOptima 1 capsule QD with food. Therapy was continued for 2 months. Follow-up examinations were performed 1 and 2 months after the start of treatment.

Results. After 2 months of treatment, combination therapy (tamsulosin + ProstOptima) showed a statistically significant superiority over monotherapy, with better trends in key indicators and a more pronounced improvement in the International Prostate Symptom Score (IPSS) and the Quality of Life (QoL) scale.

Conclusion. Combination therapy with tamsulosin and ProstOptima demonstrated high efficacy and safety in the treatment of BPH-related LUTS, as evidenced by objective urodynamic parameters and quality-of-life questionnaire data.

About the authors

Adel S. Al-Shukri

Pavlov First Saint Petersburg State Medical University

Author for correspondence.
Email: ad330@mail.ru
ORCID iD: 0000-0001-6543-8589

D. Sci. (Med.), Prof.

Russian Federation, Saint Petersburg

Maria R. Kolomiitseva

Pavlov First Saint Petersburg State Medical University

Email: ad330@mail.ru
ORCID iD: 0009-0001-9835-4055

Student

Russian Federation, Saint Petersburg

References

  1. Xu G, Dai G, Huang Z, et al. The Etiology and Pathogenesis of Benign Prostatic Hyperplasia: The Roles of Sex Hormones and Anatomy. Res Rep Urol. 2024;16:205-14. doi: 10.2147/RRU.S477396
  2. Ng M, Leslie SW, Baradhi KM. Benign Prostatic Hyperplasia. 2025.
  3. Bhat SA, Rather SA, Islam N. An overview of benign prostatic hyperplasia and its appreciation in Greco-Arab (Unani) system of medicine. Asian J Urol. 2022;9(2):109-18. doi: 10.1016/j.ajur.2021.05.008
  4. Нашивочникова Н.А. Осознанный подход к выбору консервативной терапии ДГПЖ. РМЖ. Медицинское обозрение. 2022;6(4):187-94 [Nashivochnikova NA. Informed method of choice concerning conservative therapy of BPH. Russian Medical Inquiry. 2022;6(4):187-94 (in Russian)]. doi: 10.32364/2587-6821-2022-6-4-187-194
  5. Мосоян М.С., Гилев Е.С., Айсина Н.А. Доброкачественные образования почек. СПб.: Издательство СПбГЭУ, 2022 [Mosoian MS, Gilev ES, Aisina NA. Dobrokachestvennye obrazovaniia pochek. Saint Petersburg: Izdatel'stvo SPbGEU, 2022 (in Russian)].
  6. Shah A, Shah AA, Nandakumar K, Lobo R. Mechanistic targets for BPH and prostate cancer-a review. Rev Environ Health. 2021;36(2):261-70. doi: 10.1515/reveh-2020-0051
  7. Салиев А.Р. Анализ этиологических факторов для оценки риска возникновения доброкачественной гиперплазии предстательной железы среди мужского населения ферганской долины (на примере г. Андижана). Мировая наука 2021. Проблемы и перспективы развития. 2021:42-51 [Saliev AR. Analiz etiologicheskikh faktorov dlia otsenki riska vozniknoveniia dobrokachestvennoi giperplazii predstatel'noi zhelezy sredi muzhskogo naseleniia ferganskoi doliny (na primere g. Andizhana). Mirovaia nauka 2021. Problemy i perspektivy razvitiia. 2021:42-51 (in Russian)].
  8. Нотов И.К., Залавина С.В., Позднякова С.В. Особенности микроциркуляторного русла предстательной железы у мужчин с избыточной массой тела при доброкачественной гиперплазии предстательной железы по данным иммуногистохимического выявления CD34. Вестник Волгоградского государственного медицинского университета. 2024;21(1):171-7 [Notov IK, Zalavina SV, Pozdnyakova SV. Features of the microcirculatory bed of the prostate gland in overweight men with benign prostatic hyperplasia according to immunohistochemical detection of CD34. Journal of Volgograd State Medical University. 2024;21(1):171-7 (in Russian)]. doi: 10.19163/1994-9480-2024-21-1-171-177
  9. Gucenmez S, Yildiz P, Donderici O, Serter R. The effect of testosterone level on metabolic syndrome: a cross-sectional study. Hormones (Athens). 2024;23(1):163-6. doi: 10.1007/s42000-023-00507-w
  10. Hata J, Harigane Y, Matsuoka K, et al. Mechanism of Androgen-Independent Stromal Proliferation in Benign Prostatic Hyperplasia. Int J Mol Sci. 2023;24(14):11634. doi: 10.3390/ijms241411634
  11. Wang YB, Yang L, Deng YQ, et al. Causal relationship between obesity, lifestyle factors and risk of benign prostatic hyperplasia: a univariable and multivariable Mendelian randomization study. J Transl Med. 2022;20(1):495. doi: 10.1186/s12967-022-03722-y
  12. Шалекенов Б.У., Куандыков Е.А., Шалекенов С.Б. Эффективность применения препаратов Омник и Омник Окас у пациентов с симптомами нижних мочевыводящих путей на фоне доброкачественной гиперплазии простаты (многоцентровая наблюдательная программа). Урология. 2017;5:42-7 [Shalekenov BU, Kuandykov YA, Shalekenov SB. Effectiveness of Omnic and Omnic Ocas in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia (multi-center observing program). Urologiia. 2017;5:42-7 (in Russian]).
  13. Доброкачественная гиперплазия предстательной железы. Клинические рекомендации Минздрава России 2024 г. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/6_2. Ссылка активна на 01.10.2025 [Dobrokachestvennaia giperplaziia predstatel'noi zhelezy. Klinicheskie rekomendatsii Minzdrava Rossii 2024 g. Available at: https://cr.minzdrav.gov.ru/view-cr/6_2. Accessed: 01.10.2025 (in Russian)].
  14. Elterman D, Aubé-Peterkin M, Evans H, et al. UPDATE – Canadian Urological Association guideline: Male lower urinary tract symptoms/benign prostatic hyperplasia. Can Urol Assoc J. 2022;16(8):245-56. doi: 10.5489/cuaj.7906
  15. Morgia G, Lo Giudice A, Cimino S, et al. Comparison of Serenoa repens, lycopene, and selenium versus dutasteride for the treatment of LUTS/BPH: an Italian multicenter case-control prospective study (COMP study). Front Urol. 2025;5:1565240. doi: 10.3389/fruro.2025.1565240
  16. Bevilacqua G, Carino D, Salciccia S, et al. Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study. Prostate. 2025;97(3):13877. doi: 10.1002/pros.70071
  17. Ryu YW, Lim SW, Kim JH, et al. Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urol Int. 2015;94(2):187-93. doi: 10.1159/000366521
  18. Кривобородов Г.Г., Тур Е.И. Растительный препарат на основе гексанового экстракта Serenoa repens у пациентов с симптомами нижних мочевыводящих путей. РМЖ. 2021;29(4):40-4 [Krivoborodov GG, Tur EI. Herbal medicinal product based on the hexane extract of Serenoa repens in patients with lower urinary tract symptoms. RMJ. 2021;4:40-4 (in Russian)].
  19. Alcaraz A, Gacci M, Ficarra V, et al. Efficacy and Safety of the Hexanic Extract of Serenoa repens vs. Watchful Waiting in Men with Moderate to Severe LUTS-BPH: Results of a Paired Matched Clinical Study. J Clin Med. 2022;11(4):967. doi: 10.3390/jcm11040967
  20. Сивков А.В., Кирпатовский В.И. Гипотеза о возможных механизмах терапевтического действия гексанового экстракта Serenoa repens на состояние гипертрофированного мочевого пузыря в соответствии с патогенезом его дисфункции при инфравезикальной обструкции. Экспериментальная и клиническая урология. 2023;16(2):16-30 [Sivkov AV, Kirpatovsky VI. Hypothesis about the possible mechanisms of therapeutic action of Serenoa repens hexane extract on the hypertrophied bladder in accordance with the pathogenesis of its dysfunction caused by bladder outlet obstruction. Experimental and Сlinical Urology. 2023;16(2):16-30 (in Russian)]. doi: 10.29188/2222-8543-2023-16-2-16-30
  21. Бачурин Г.В. Характеристика инфекции мочевых путей больных мочекаменной болезнью и ее комбинированное лечение на современном этапе. Урология. 2015;19(4):30-3 [Bachurin GV. Kharakteristika infektsii mochevykh putei bol'nykh mochekamennoi bolezn'iu i ee kombinirovannoe lechenie na sovremennom etape. Urologiia. 2015;19(4):30-3 (in Russian)].
  22. Trivisonno LF, Sgarbossa N, Alvez GA, et al. Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement: A systematic review and meta-analysis. Investig Clin Urol. 2021;62(5):520-34. doi: 10.4111/icu.20210254
  23. Vela-Navarrete R, Alcaraz A, Rodríguez-Antolín A, et al. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon®) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int. 2018;122(6):1049-105. doi: 10.1111/bju.14362
  24. Амдий Р.Э., Симанов Р.Н. Современные возможности лечения доброкачественной гиперплазии предстательной железы и симптомов нижних мочевыводящих путей: новые данные и опыт клинического применения гексанового экстракта плодов Serenoa repens. РМЖ. Медицинское обозрение. 2024;8(4):228-34 [Amdiy RE, Simanov RN. Modern treatment options for benign prostatic hyperplasia and lower urinary tract symptoms: new data and clinical picture of the hexane extract of Serenoa repens fruit. Russian Medical Inquiry. 2024;8(4):228-34 (in Russian)]. doi: 10.32364/2587-6821-2024-8-4-7
  25. Cornu JN, Gacci M, Hashim H, et al. EAU Guidelines on Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS). Available at: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-Neurogenic-Male-LUTS-2025.pdf. Accessed: 01.10.2025.
  26. Глыбочко П.В., Зезеров Е.Г., Бутнару Д.В., и др. Витамины и каротиноиды в динамике процесса онкогенеза предстательной железы. Сеченовский вестник. 2011;3-4(5-6):4-13 [Glybochko PV, Zezerov EG, Butnaru DV, et al. Vitaminy i karotinoidy v dinamike protsessa onkogeneza predstatel'noi zhelezy. Sechenovskii vestnik. 2011;3-4(5-6):4-13 (in Russian)].
  27. Агавердиев Б.Н., Асфандияров Ф.Р., Круглов В.А., и др. Антиоксидантная терапия в коррекции ДНК-фрагментации сперматозоидов. Экспериментальная и клиническая урология. 2024;17(2):26-34 [Agaverdiev BN, Asfandiyarov FR, Kruglov VA, et al. Antioxidant therapy in the correction of sperm DNA fragmentation. Experimental and Clinical Urology. 2024;17(2):26-34 (in Russian)]. doi: 10.29188/2222-8543-2024-17-2-26-34
  28. Osadchuk L, Kleshchev M, Danilenko A, Osadchuk A. Impact of seminal and serum zinc on semen quality and hormonal status: A population-based cohort study of Russian young men. J Trace Elem Med Biol. 2021;68:126855. doi: 10.1016/j.jtemb.2021.126855
  29. Елисеева Т. Селен (Se) – значение для организма и здоровья + 30 лучших источников. Журнал здорового питания и диетологии. 2023;(19):55-64 [Eliseeva T. Selen (Se) – znachenie dlia organizma i zdorov'ia + 30 luchshikh istochnikov. Zhurnal zdorovogo pitaniia i dietologii. 2023;(19):55-64 (in Russian)]. doi: 10.59316/.vi19.160
  30. Barbaresi U, Dicuio M, Mineo Bianchi F, et al. Efficacy of Serenoa repens lipido-sterolic extract alone or in combination with propolis polyphenols and Boswellia serrata extract suppositories on PSA level and symptoms in patients affected by lower urinary tract disorders. Arch Ital Urol Androl. 2025;97(3):13877. doi: 10.4081/aiua.2025.13877
  31. Ryu YW, Lim SW, Kim JH, et al. Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urol Int. 2015;94(2):187-93. doi: 10.1159/000366521
  32. Veltri RW, Marks LS, Miller MC, et al. Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism. Urology. 2002;60:617-22. doi: 10.1016/s0090-4295(02)01838-1

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Al-Shukri A.S., Kolomiitseva M.R. Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).